UPDATE: Goldman Sachs Reinstates Neutral on BioMed Realty as Acquisitions Broaden Their Portfolio
June 14, 2013 at 09:13 AM EDT
In a report published on Friday, Goldman Sachs analyst Matthew Rand reinstated a Neutral rating on BioMed Realty (NYSE: BMR ) and maintained its $21 price target on the company. In the report, Goldman Sachs commented that, "We have removed the Not Rated designation from BioMed Realty shares. We rate
